A Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Subjects
Overview
- Phase
- Phase 1
- Intervention
- JNJ-54861911 3 mg
- Conditions
- Healthy
- Sponsor
- Janssen Research & Development, LLC
- Enrollment
- 70
- Primary Endpoint
- The number of volunteers who experience adverse events as a measure of safety and tolerability of JNJ-54861911 after multiple dose administration in the target dose range and above
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-ascending dose JNJ-54861911 which is currently being developed for the treatment of Alzheimer's disease.
Detailed Description
This multiple ascending dose study is anticipated to enroll 5 cohorts (small groups). Cohorts 1 to 4 will be conducted as a double-blind (neither investigator nor participant knows which treatment the participant receives), randomized (participants are assigned different treatments based on chance), placebo-controlled (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) study. Cohort 5 will be performed as an open-label study (all people know the identity of the intervention), using a recently made available solid dose formulation of JNJ-54861911. The study is designed to evaluate the safety (side effects), tolerability, pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time, ie, what the body does to the drug), and pharmacodynamics (what the drug does to the body) of JNJ-54861911. The study population will consist of approximately 38 healthy elderly participants divided among approximately 5 cohorts. For all participants the study will consist of 3 phases: eligibility screening examination phase (between 28 and 2 days prior to the first dose administration), a 14-day double-blind (Cohorts 1 to 4) or open-label (Cohort 5) treatment phase, and a follow-up examination phase (within 7 to 14 days after last dose administration). Participants who successfully complete the screening examination and are considered eligible to participate will be admitted to the clinical unit on Day -1 before administration of the study drug. Cohorts 1 to 4 will consist of 8 participants. Within these cohorts, participants will be randomly assigned to double-blind treatment with an oral suspension of JNJ-54861911 3 mg, 10 mg, 30 mg, or 80 mg (n=6/cohort) or matching placebo (n=2/cohort). Cohorts 1 to 4 will be used for dose escalations and assessing the maximal tolerated dose using an oral suspension of JNJ-54861911. Cohort 5 will consist of 6 participants who will all receive open-label treatment with a single solid dose formulation of JNJ 54861911 25 mg. Cohort 5 will assess if the recently made available solid dose formulation (strength 25 mg) has similar pharmacokinetic properties and pharmacodynamic effects as the oral suspension at a dose level in the range that has been assessed earlier (Cohorts 1 to 4) and was found to be safe and well tolerated. All cohorts (Cohorts 1 to 5) will follow the same study assessments. Participants will be administered single doses of study medication on Days 1 to 14. Following and/or during each dose level of the study (cohort), the observed safety and tolerability profile of the ongoing cohort and previous cohort will be evaluated and doses will only be increased if the observed safety and tolerability profile is acceptable. Plasma pharmacokinetic profiles of the ongoing cohort (up to and including Day 7) and plasma and cerebrospinal fluid (CSF) pharmacokinetic profiles as well as CSF plasma amyloid beta (Aβ) profiles of the previous cohort (up to and including Day 14) if applicable, will support dose increase decisions. Actual dose levels as well as the magnitude of dose escalation will depend on the results of the ongoing single-ascending dose study (54861911ALZ1001), the observed safety and tolerability profile, as well as the observed exposures. Participants will be discharged from the clinical unit after the last study assessment on Day 16 or approximately 24 hours after the indwelling catheter has been removed, whatever occurs later. If discharged on Day 16, participants will return to the clinical unit on Day 17 (72 hours post-dose Day 14) for plasma pharmacokinetic sampling. Safety assessments will be performed throughout the study. The maximal study duration for a participant will not exceed 8 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Good general health
- •Body mass index (BMI) between 18 and 32 kg/m2, inclusive
- •Women must be postmenopausal, permanently sterilized or otherwise be incapable of pregnancy
- •Must adhere to required contraception during and for 3 months after study
Exclusion Criteria
- •Clinically significant medical or psychiatric illness
- •Alcohol or substance abuse; excessive nicotine or caffeine use
- •Recently received an investigational drug, vaccine, or invasive medical device
- •Unable to abide by protocol restrictions on use of other medications
- •Relevant history of lower back pain or scoliosis and/or major (lumbar) back surgery
- •Allergic to local anesthetics and/or iodine
Arms & Interventions
Cohort 1: JNJ-54861911 3 mg
Participants will be administered single doses of JNJ-54861911 on Days 1 to 14. Initially the doses will be once per day, but the frequency of daily dosing (eg, once-daily, twice-daily, three times daily) may change prior to or during study conduct depending on the pharmacokinetic data from the ongoing single-ascending dose study (54861911ALZ1001) or ongoing cohorts in this current study. Actual dose levels as well as the magnitude of dose escalation will depend on the results of the ongoing single-ascending dose study, the observed safety and tolerability profile as well as the observed exposures.
Intervention: JNJ-54861911 3 mg
Cohort 2: JNJ-54861911 10 mg
Intervention: JNJ-54861911 10 mg
Cohort 3: JNJ-54861911 30 mg
Intervention: JNJ-54861911 30 mg
Cohort 4: JNJ-54861911 80 mg
Intervention: JNJ-54861911 80 mg
Cohort 5: JNJ-54861911 25 mg
Intervention: JNJ-54861911 25 mg
Cohorts 1-4: Placebo
Participants in Cohorts 1-4 will receive matching placebo.
Intervention: Placebo
Outcomes
Primary Outcomes
The number of volunteers who experience adverse events as a measure of safety and tolerability of JNJ-54861911 after multiple dose administration in the target dose range and above
Time Frame: Up to 72 hours
Secondary Outcomes
- Maximal tolerated dose (MTD) or maximal feasible exposure level of JNJ-54861911 after multiple dose administration(Up to 72 hours)
- Maximum observed plasma/cerebrospinal fluid (CSF) concentration (Cmax) of JNJ-54861911(Up to 72 hours)
- Levels of amyloid beta (Aβ) fragments (Aβ1-37, Aβ1-38, Aβ1-40 and Aβ1-42) in CSF after multiple dose administration(Up to 36 hours)
- Time to reach maximum observed plasma/CSF concentration of JNJ-54861911(Up to 72 hours)
- Area under the plasma/CSF concentration-time curve (AUC) from time 0 to t hours of JNJ-54861911(Up to 72 hours)
- Half-life of JNJ-54861911(Up to 72 hours)